Amikacin target and observed exposures in ELF; data are expressed as mean ± SD
| . | Target . | Observeda . | |
|---|---|---|---|
| inhaled amikacin monotherapy . | combination of inhaled amikacin and intravenous meropenem . | ||
| Peak (mg/L) | 5251 | 4668 ± 289 | 4904 ± 611 |
| Trough (mg/L) | 507 | 547 ± 118 | 480 ± 76 |
| AUC0–12 (mg·h/L) | 17 941 | 17 613 ± 868 | 17 273 ± 481 |
| . | Target . | Observeda . | |
|---|---|---|---|
| inhaled amikacin monotherapy . | combination of inhaled amikacin and intravenous meropenem . | ||
| Peak (mg/L) | 5251 | 4668 ± 289 | 4904 ± 611 |
| Trough (mg/L) | 507 | 547 ± 118 | 480 ± 76 |
| AUC0–12 (mg·h/L) | 17 941 | 17 613 ± 868 | 17 273 ± 481 |
aObserved from measured concentrations during in vitro modelling experiments.
Amikacin target and observed exposures in ELF; data are expressed as mean ± SD
| . | Target . | Observeda . | |
|---|---|---|---|
| inhaled amikacin monotherapy . | combination of inhaled amikacin and intravenous meropenem . | ||
| Peak (mg/L) | 5251 | 4668 ± 289 | 4904 ± 611 |
| Trough (mg/L) | 507 | 547 ± 118 | 480 ± 76 |
| AUC0–12 (mg·h/L) | 17 941 | 17 613 ± 868 | 17 273 ± 481 |
| . | Target . | Observeda . | |
|---|---|---|---|
| inhaled amikacin monotherapy . | combination of inhaled amikacin and intravenous meropenem . | ||
| Peak (mg/L) | 5251 | 4668 ± 289 | 4904 ± 611 |
| Trough (mg/L) | 507 | 547 ± 118 | 480 ± 76 |
| AUC0–12 (mg·h/L) | 17 941 | 17 613 ± 868 | 17 273 ± 481 |
aObserved from measured concentrations during in vitro modelling experiments.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
